$2.32
4.50%
Nasdaq, Sep 02, 10:16 pm CET
ISIN
US29664W1053
Symbol
ESPR

Esperion Therapeutics, Inc. Stock price

$2.32
+0.83 55.70% 1M
+0.74 46.84% 6M
+0.12 5.45% YTD
+0.49 26.78% 1Y
-5.54 70.48% 3Y
-34.57 93.71% 5Y
-46.67 95.26% 10Y
-12.18 84.00% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.10 4.50%
ISIN
US29664W1053
Symbol
ESPR
Industry

Key metrics

Basic
Market capitalization
$467.8m
Enterprise Value
$679.9m
Net debt
$212.2m
Cash
$86.1m
Shares outstanding
200.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.7 | 1.3
EV/Sales
2.5 | 1.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-113.1%
Return on Equity
13.3%
ROCE
-73.4%
ROIC
-36.3%
Debt/Equity
-0.7
Financials (TTM | estimate)
Revenue
$268.1m | $367.5m
EBITDA
$-35.3m | $34.1m
EBIT
$-35.4m | $32.3m
Net Income
$-104.0m | $-28.9m
Free Cash Flow
$-124.5m
Growth (TTM | estimate)
Revenue
-3.5% | 10.6%
EBITDA
-804.0% | -37.5%
EBIT
-811.6% | -40.6%
Net Income
-5.6% | 44.2%
Free Cash Flow
-1,157.5%
Margin (TTM | estimate)
Gross
61.6%
EBITDA
-13.2% | 9.3%
EBIT
-13.2%
Net
-38.8% | -7.9%
Free Cash Flow
-46.4%
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
11.3%
Employees
304
Rev per Employee
$1.1m
Show more

Is Esperion Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Esperion Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Esperion Therapeutics, Inc. forecast:

10x Buy
71%
3x Hold
21%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Esperion Therapeutics, Inc. forecast:

Buy
71%
Hold
21%
Sell
7%

Financial data from Esperion Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
268 268
3% 3%
100%
- Direct Costs 103 103
104% 104%
38%
165 165
27% 27%
62%
- Selling and Administrative Expenses 159 159
3% 3%
59%
- Research and Development Expense 41 41
28% 28%
15%
-35 -35
804% 804%
-13%
- Depreciation and Amortization 0.11 0.11
175% 175%
0%
EBIT (Operating Income) EBIT -35 -35
812% 812%
-13%
Net Profit -104 -104
6% 6%
-39%

In millions USD.

Don't miss a Thing! We will send you all news about Esperion Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Esperion Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –
Neutral
GlobeNewsWire
27 days ago
ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Positive
The Motley Fool
28 days ago
Esperion (ESPR) Q2 Revenue Jumps 12%
More Esperion Therapeutics, Inc. News

Company Profile

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Head office United States
CEO Sheldon Koenig
Employees 304
Founded 1998
Website www.esperion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today